
Ceribell received FDA 510(k) clearance for quantitative EEG trending and amplitude-integrated EEG analysis, including alpha-delta ratio and burst suppression monitoring. The clearance covers all ages, including neonates, with a software rollout planned for early 2027.
Ceribell reported a trio of milestones alongside its Q2 results. CMS granted a New Technology Add-on Payment of up to $2,171 per Medicare case for its Delirium Monitor, and the FDA cleared new epileptiform detection and artifact-reduction algorithms for its cloud portal. Revenue rose 33% to $28.1 million, and the company raised full-year guidance. Ceribell makes a rapid, portable EEG headband that lets non-specialists assess seizures and delirium at the bedside, and is building its seizure-detection base into a broader brain-monitoring platform.